Primary CNS Lymphoma Clinical Trial
Official title:
Combination of Rituximab and Methotrexate Followed by Rituximab and Cytarabine in Elderly Patients With Primary CNS Lymphoma
This study was conducted to evaluate the 2-year progression free survival rate of elderly patients with primary CNS lymphoma followed by combination of rituximab and methotrexate followed by rituximab and cytarabine.
As described, standard therapy for patients with primary CNS lymphoma is not based on a high level of evidence yet, and studies in elderly patients with this disease are very limited. Based on the Korea National Cancer Incidence Database, it is estimated that about 100 ~ 150 cases of primary central nervous system lymphoma are diagnosed per year in Korea, but there is no analysis through prospective studies. As described previously, MTX monotherapy in elderly patients is relatively safe and does not reduce clinical utility. Although the autologous therapy may consider autologous stem cell transplantation, it is difficult to apply in elderly patients. Brain radiation therapy is not a primary consideration because it may cause neurological sequelae, especially in elderly patients. High-dose cytarabine is a safely administered drug that has been used extensively in clinical studies involving the treatment of elderly patients.Rituximab has not been studied prospectively for medications, doses, and intervals that are expected to play a role in patients with primary CNS lymphoma, as described above, and may be caused by reducing the number of cytotoxic anticancer drugs in elderly patients And to reduce the treatment effect. Therefore, the authors propose a two-phase study in which R-A induction therapy is performed after R-M induction therapy in elderly patients with primary CNS lymphoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05036564 -
Diagnosis; Objective RespOnse; THErApy
|
N/A | |
| Recruiting |
NCT04627753 -
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
|
Phase 2 | |
| Recruiting |
NCT05518383 -
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
|
Phase 4 | |
| Recruiting |
NCT05425654 -
RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
|
Phase 2 | |
| Terminated |
NCT04073147 -
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT04443829 -
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04006561 -
Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
|
||
| Recruiting |
NCT04656431 -
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT04464200 -
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
|
Phase 1 | |
| Recruiting |
NCT02934204 -
Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04947319 -
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
|
Phase 2 | |
| Active, not recruiting |
NCT04134117 -
Tisagenlecleucel In Primary CNS Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT03212807 -
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
|
Phase 2 |